August J. Troendle Sells 3,987 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDPGet Free Report) CEO August J. Troendle sold 3,987 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $395.22, for a total transaction of $1,575,742.14. Following the completion of the sale, the chief executive officer now owns 660,351 shares in the company, valued at $260,983,922.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Medpace Stock Performance

Shares of MEDP opened at $385.70 on Friday. The company’s 50 day moving average price is $394.56 and its 200 day moving average price is $348.82. Medpace Holdings, Inc. has a 52 week low of $202.02 and a 52 week high of $421.00. The company has a market capitalization of $11.95 billion, a PE ratio of 39.32, a PEG ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDPGet Free Report) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same period in the previous year, the firm posted $2.27 earnings per share. The firm’s revenue was up 17.7% on a year-over-year basis. On average, equities analysts forecast that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MEDP. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Mizuho began coverage on shares of Medpace in a research report on Tuesday. They issued a “buy” rating and a $435.00 target price on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Robert W. Baird lifted their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Finally, TD Cowen began coverage on shares of Medpace in a research report on Wednesday. They issued a “buy” rating and a $452.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $443.14.

Get Our Latest Report on Medpace

Institutional Trading of Medpace

Large investors have recently added to or reduced their stakes in the business. RiverPark Advisors LLC bought a new stake in Medpace in the fourth quarter worth approximately $26,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the fourth quarter worth approximately $26,000. Rise Advisors LLC bought a new stake in Medpace in the first quarter worth approximately $27,000. Mather Group LLC. bought a new stake in Medpace in the first quarter worth approximately $28,000. Finally, GAMMA Investing LLC bought a new stake in Medpace in the fourth quarter worth approximately $30,000. 77.98% of the stock is owned by institutional investors.

About Medpace

(Get Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.